Signal mining and analysis of adverse drug events for gilteritinib

LIU Yang; HAN Minzhen; XIA Jie; HU Hanshuai; YAO Lei; LAN Xue; LIU Qian; WANG Jinxingyi

doi:10.6039/j.issn.1001-0408.2024.15.15

您当前的位置：

首页 >

文章列表页 >

Signal mining and analysis of adverse drug events for gilteritinib

更新时间：2024-08-11

- Signal mining and analysis of adverse drug events for gilteritinib
- ZHONGGUO YAOFANG Vol. 35, Issue 15, Pages: 1888-1892(2024)
- 作者机构：
  
  贵州医科大学第二附属医院药剂科，贵州凯里　556000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.15.15
  CLC： R979.1
- Published：15 August 2024，
  
  Received：04 March 2024，
  
  Revised：24 June 2024，
- 稿件说明：
扫描看全文
刘洋,韩敏珍,夏杰等.吉瑞替尼的不良事件信号挖掘与分析 ^Δ[J].中国药房,2024,35(15):1888-1892.

LIU Yang,HAN Minzhen,XIA Jie,et al.Signal mining and analysis of adverse drug events for gilteritinib[J].ZHONGGUO YAOFANG,2024,35(15):1888-1892.
刘洋,韩敏珍,夏杰等.吉瑞替尼的不良事件信号挖掘与分析 ^Δ[J].中国药房,2024,35(15):1888-1892. DOI： 10.6039/j.issn.1001-0408.2024.15.15.

LIU Yang,HAN Minzhen,XIA Jie,et al.Signal mining and analysis of adverse drug events for gilteritinib[J].ZHONGGUO YAOFANG,2024,35(15):1888-1892. DOI： 10.6039/j.issn.1001-0408.2024.15.15.

摘要

目的

挖掘吉瑞替尼的不良事件（ADE）信号，为临床安全用药提供参考。

方法

收集美国FDA不良事件报告系统（FAERS）2018年2月1日至2023年12月31日上报的以吉瑞替尼为首要怀疑药物的ADE报告，采用报告比值比（ROR）法和比例报告比值比（PRR）法进行数据挖掘。利用《国际医学用语词典》（24.1版）药物ADE术语集中的首选术语（PT）和系统器官分类（SOC）进行分类统计。

结果

共得到吉瑞替尼ADE报告2 755份，包含676个ADE信号（阳性ADE信号95个），累及313个PT，涉及25个SOC。其中，有9个ADE信号未被其药品说明书提及。信号强度排名前5位的PT分别为肝功能异常、血小板计数降低、发热性中性粒细胞减少症、肺炎和骨髓抑制；阳性信号数排名前6位的SOC分别为各类检查，全身性疾病及给药部位各种反应，呼吸系统、胸及纵隔疾病，感染及侵染类疾病，心脏器官疾病，各类神经系统疾病。其药品说明书未提及的ADE包括肺炎、骨髓抑制、血细胞减少症、败血症、出血、感染（未特指）、感染性休克、呼吸衰竭、曲霉菌感染。

结论

应用吉瑞替尼时，临床除需关注肝功能异常、血小板减少症等常见ADE外，还应监测药品说明书未提及且信号较强的ADE，如肺炎、骨髓抑制、血细胞减少症、败血症、出血、感染（未特指）、感染性休克、呼吸衰竭、曲霉菌感染、血肌酐升高及间质性肺疾病等。

Abstract

OBJECTIVE

To mine the adverse drug events （ADE） signals for gilteritinib， and provide a reference for safe drug use in clinic.

METHODS

ADE reports with gilteritinib as the primary suspected drug were extracted from the FDA Adverse Event Reporting System （FAERS） database from February 1st， 2018 to December 31st， 2023. Reporting odds ratio （ROR） and proportional reporting ratio （PRR） were applied to detect the risk signals from the data in the FAERS database. The classification and statistics of collected signal data were conducted by using the preferred term （PT） and systemic organ class （SOC） in ADE terminology set of the

Medical Dictionary for Regulatory Activities

（24.1 edition）.

RESULTS

Totally， 2 755 gilteritinib-related ADE reports were collected from the database， involving 676 ADE signals （95 positive signals）， 313 PTs and 25 SOCs. Among them， nine signals were not recorded in the package insert. The top 5 PTs consisted of abnormal liver function， decreased platelet count， febrile neutropenia， pneumonia and myelosuppression. The top 6 SOCs for positive signal counts were examinations， general disorders and administration site conditions， respiratory， thoracic and mediastinal disorders， infections and infestations， heart organ disorders， and nervous system disorders. ADEs not recorded in the drug package insert included pneumonia， myelosuppression， decreased blood cell count， sepsis， hemorrhage， infection （not specifically referred to）， septic shock， respiratory failure， and aspergillosis.

CONCLUSIONS

In addition to paying attention to common ADEs such as liver dysfunction and thrombocytopenia， it is necessary to monitor ADEs with strong signals that are not mentioned in the drug instructions when using gefitinib， such as pneumonia， bone marrow suppression， cytopenia， sepsis， bleeding， infection （not specifically referred to）， septic shock， respiratory failure， Aspergillus infection， elevated serum creatinine and interstitial lung disease.

关键词

吉瑞替尼药品不良事件药物警戒数据挖掘

Keywords

adverse drug eventspharmacovigilancedata mining

references

SHIMONY S，STAHL M，STONE R M. Acute myeloid leukemia：2023 update on diagnosis，risk-stratification，and management[J]. Am J Hematol，2023，98（3）：502-526.

DAVER N，VENUGOPAL S，RAVANDI F. FLT3 mutated acute myeloid leukemia：2021 treatment algorithm[J]. Blood Cancer J，2021，11（5）：104.

赵爽，张莹，王相峰，等. 治疗FLT3突变复发或难治性急性髓系白血病的新药：吉特替尼[J]. 肿瘤药学，2019，9（6）：957-960.

ZHAO S，ZHANG Y，WANG X F，et al. New drugs for FLT3 mutant recurrence or refractory acute myeloid leukemia：gilteritinib[J]. Anti Tumor Pharm，2019，9（6）：957-960.

FDA.XOSPATA*（gilteritinib） tablets，for oral administration[EB/OL].[2024-02-11]. https：//www.astellas.com.cn/system/files/2_gilteritinib_fumarate_tablets.pdfhttps://www.astellas.com.cn/system/files/2_gilteritinib_fumarate_tablets.pdf.

PAUDEL A，DHITAL R，AREOYE G，et al. Sweet’s syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor[J]. J Community Hosp Intern Med Perspect，2020，10（3）：275-278.

KIM R S，YAGHY A，WILDE L R，et al. An iridociliochoroidal myeloid sarcoma associated with relapsed acute myeloid leukemia with FLT3-ITD mutation，treated with gilteritinib，an FLT3 inhibitor[J]. JAMA Ophthalmol，2020，138（4）：418-419.

GROßE-MICHAELIS I，PROESTEL S，RAO R M，et al. MedDRA labeling groupings to improve safety communication in product labels[J]. Ther Innov Regul Sci，2023，57（1）：1-6.

EVANS S J，WALLER P C，DAVIS S. Use of proportional reporting ratios （PRRs） for signal generation from spontaneous adverse drug reaction reports[J]. Pharmacoepidemiol Drug Saf，2001，10（6）：483-486.

DAVER N，PERL A E，MALY J，et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia[J]. J Clin Oncol，2022，40（35）：4048-4059.

JAMES A J，SMITH C C，LITZOW M，et al. Pharmacokinetic profile of gilteritinib：a novel FLT-3 tyrosine kinase inhibitor[J]. Clin Pharmacokinet，2020，59（10）：1273-1290.

SCHWAIBLMAIR M，BEHR W，HAECKEL T，et al. Drug induced interstitial lung disease[J]. Open Respir Med J，2012，6：63-74.

VAN LEMMEN M，VAN DER SCHRIER R，DAHAN A，et al. Pharmacology of viable mechanism agnostic respiratory stimulants for the reversal of drug-induced respiratory depression in humans[J]. Expert Opin Drug Metab Toxicol，2023，19（10）：671-679.

TOLLKUCI E，TRAN T，MYERS R. Gilteritinib admini- stration in a hemodialysis patient[J]. J Oncol Pharm Pract，2021，27（5）：1255-1257.

MOLICA M，PERRONE S，ROSSI M. Gilteritinib：the story of a proceeding success into hard-to-treat FLT3- mutated AML patients[J]. J Clin Med，2023，12（11）：3647.

PERL A E，ALTMAN J K，CORTES J，et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia：a multicentre，first-in-human，open-label，phase 1-2 study[J]. Lancet Oncol，2017，18（8）：1061-1075.

SUGAMORI H，LEE T，MITOMI T，et al. Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan[J]. Jpn J Clin Oncol，2022，52（7）：766-773.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Signal mining and analysis of adverse drug events of baloxavir marboxil based on American FAERS

Signal detection and analysis of the adverse events of ustekinumab based on OpenFDA database

Excavation for adverse events signals of atezolizumab

计算机技术在医疗机构药品安全性监测中的应用进展Δ

数据挖掘技术在药品不良反应监测领域中的应用

Related Author

LYU Lingtong

YANG Wenbao

LIN Jing

CHEN Huiqing

XU Ting

JIA Shuyun

DI Panpan

HU Yunfei

Related Institution

Dept. of Pharmacy， Jinan Shizhong District People’s Hospital

Dept. of Western Medicine Pharmacy， Jinan Shizhong District People’s Hospital

Dept. of Pharmacy， the Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Pharmacy Intravenous Admixture Services，Bozhou Municipal People’s Hospital

School of Traditional Chinese Medicine， Bozhou University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰